Outlook Therapeutics, Inc.

OTLK

$0.65

+3.62%

N/A+$0.02

Healthcare

Biotechnology

NASDAQ

Active Trading

Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal ...

Insider Transactions of OTLK

Acquisitions (A)

Since Jul 21, 2026

Disposals (D)

Since Jul 21, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Sep 1, 2026	Lundquist Kevin Michael	officer: Chief Financial Officer	Employee Stock Option (Right to Buy)	A	500,000	$0.63
Sep 1, 2026	Lundquist Kevin Michael	—	—	—	0	—
Aug 14, 2026	Jahr Robert Charles	director, officer: Chief Executive Officer	Common Stock	A	151,515	$0.99
Aug 14, 2026	Jahr Robert Charles	director, officer: Chief Executive Officer	Warrants (right to buy)	A	151,515	$1.10
Aug 14, 2026	KENYON LAWRENCE A	director, officer: Chief Financial Officer	Common Stock	A	101,010	$0.99

Insider Trading Snapshot

Acquisitions (A)

Disposals (D)

Total Shares Bought

6,361,030

Total Shares Sold

Monthly Insider Activity

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Transactions by Title - Shares

X-axis: shares, sorted by total shares desc

Transactions by Title - Counts

X-axis: counts, sorted by A+D counts desc

Key People: Buy/Sell Activity and Price

Jahr Robert Charles

director, officer: Chief Executive Officer • 2 txns

KENYON LAWRENCE A

director, officer: Chief Financial Officer • 3 txns

Lundquist Kevin Michael

officer: Chief Financial Officer • 2 txns

Sukhtian Ghiath M.

director, 10 percent owner: • 2 txns

Transactions Table

Date	Executive	Title	Security	Side	Shares	Price	Value
Sep 1, 2026	Lundquist Kevin Michael	officer: Chief Financial Officer	Employee Stock Option (Right to Buy)	A	500,000	$0.63	$315,000.00
Sep 1, 2026	Lundquist Kevin Michael	—	—	—	0	—	—
Aug 14, 2026	Jahr Robert Charles	director, officer: Chief Executive Officer	Common Stock	A	151,515	$0.99	$149,999.85
Aug 14, 2026	Jahr Robert Charles	director, officer: Chief Executive Officer	Warrants (right to buy)	A	151,515	$1.10	$166,666.50
Aug 14, 2026	KENYON LAWRENCE A	director, officer: Chief Financial Officer	Common Stock	A	101,010	$0.99	$99,999.90
Aug 14, 2026	KENYON LAWRENCE A	director, officer: Chief Financial Officer	Warrants (right to buy)	A	101,010	$1.10	$111,111.00
Aug 12, 2026	Sukhtian Ghiath M.	director, 10 percent owner:	Common Stock	A	2,525,252	$0.99	$2,499,999.48
Aug 12, 2026	Sukhtian Ghiath M.	director, 10 percent owner:	Warrants (right to buy)	A	2,525,252	$1.10	$2,777,777.20
Jul 29, 2026	Sukhtian Faisal Ghiath	director	Common Stock	A	95,398	$1.05	$99,996.18
Jul 21, 2026	KENYON LAWRENCE A	director, officer: Chief Financial Officer	Stock Option (Right to Buy)	A	210,078	$1.43	$300,495.57

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer